Abstract: Twice weekly administration of an analog to a Vagifem tablet which only contains 10 ?g of active material has a sufficient effect.

Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

Abstract: The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as polynucleotide constructs encoding such variants, vectors and host cells comprising and expressing the polynucleotide, pharmaceutical compositions, uses and methods of treatment.

Abstract: The invention concerns novel coagulation factor VII variants, wherein the Leu residue in position 305 or the Phe residue in position 374 of SEQ ID NO 1 has been replaced by another amino acid residue which can be encoded by nucleic acid constructs and, optionally, wherein at least one other amino acid residue in the remaining positions in the protease domain has been replaced by another amino acid residue which can be encoded by nucleic acid constructs; with the proviso that the variant is not FVII(Ala305).

Abstract: The present invention provides preparations of Factor VIIa polypeptides or Factor VIIa-related polypeptides that exhibit predetermined glycoform patterns. The preparations of the invention exhibit improved functional properties and are useful for treating Factor VII-mediated conditions.

Abstract: A medication delivery device comprising a system that is able to sense if the delivery device is in actual physical contact with a human being or if the delivery device has been abandoned. The system comprises an electronic control and a touch sensitive switch preferably formed as a part of the housing of the medication delivery device. The housing can be divided into two parts each constituting separate electrical conductors being spaced apart from each other by an insulating material. When the two parts a temporarily bridged e.g. by the skin of a human being a direct current path between the parts are created, which can provide an electrical signal at the electronic control. When a dose has been set, absence of the signal will cause the electronic control to cancel the set dose and to sound an alarm.

Abstract: The present invention relates to halo sulfonyl aryl boronates of the general formula (I): wherein Arylene designates a carbocyclic or heterocyclic, aromatic ring system comprising 1-3 rings; R1, R2 and R3 are, independently, hydrogen, C1-6alkyl, C1-6alkoxy, halogen, nitro, cyano or phenyl; X is fluoro, chloro or bromo; and Y is a boroxine moiety attached via a bond from Arylene to one of the boron atoms of a boroxine ring which ring has a group of the formula -Arylene(R1)(R2)(R3)SO2X, wherein Arylene, R1, R2, R3 and X are as defined above, at each of the other two boron atoms of the boroxine ring, or Y is a boronic acid group or a boronic ester group. The invention also relates to the preparation of the compounds of formula (I) and to their use in organic synthesis.

Abstract: The present invention relates to protracted human insulin derivatives in which the A21 and the B3 amino acid residues are, independently, any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys; PheB1 may be deleted; the B30 amino acid residue is (a) a non-codable, lipophilic amino acid having from 10 to 24 carbon atoms, in which case an acyl group of a carboxylic acid with up to 5 carbon atoms is bound to the ?-amino group of LysB29; or (b) the B30 amino acid residue is deleted or is any amino acid residue which can be coded for by the genetic code except Lys, Arg and Cys, in any of which cases the ?-amino group of LysB29 has a lipophilic substituent; and any Zn2+ complexes thereof with the proviso that when B30 is Thr or Ala and A21 and B3 are both Asn, and PheB1 is present, then the insulin derivative is always present as a Zn2+ complex.

Abstract: A process for producing high amount of proteins or polypeptides in yeast is disclosed. The process makes use of the CIT1 yeast promoter or a functional part or variant thereof. Examples of polypeptides which are expressed in high yields are insulin or insulin analogues or GLP1.

Abstract: A solid composition containing a meiosis activating substance can be prepared by adding a protein or a phosperglycid.

Abstract: The invention relates to a pharmaceutical composition comprising Factor VIIa for subcutan, intramuscular or interdermal administration. Factor VIIa administered subcutanously, intramuscularly or intradermally shows a sufficient transport into the bloodstream in biologically active form and in adequate concentrations, and favorable pharmacokinetic properties.

Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.

Abstract: Disclosed is a method of preparing zinc free rapid acting insulin analogue. In one embodiment insulin crystals are prepared by providing a solution of an analogue having a pH between 7 and 9.5. The solution is mixed with a salt of an alkali metal or salt and formed crystals are recovered.

Abstract: A dose setting device for a delivery system has a piston rod (6, 9) which successively presses a piston (2) into a cylinder ampoule (1). Doses are set by rotating a second part (9) of the piston rod (6, 9) in relation to a first part (6). The two parts are connected by mating threads so that the total length of the piston rod (6, 9) is increased proportional to the angle of rotation, and a point (18) on the second part is moved away from a stop position fixed in relation to a housing (5) The set dose is delivered when the point (18) is moved back to the stop position. The first part (6) can be axially displaced but not rotated in the housing (5), and the second part (9) can both rotate and be axially displaced. The first part (6) is maintained in abutment with the piston (2) and the second part (9) is coupled to be rotated by a dose setting wheel (20).

Abstract: A linear actuator comprising a first member (1) and a second member (2) provided with internal threads (6,8) cut in opposite directions and an intermediary member (3) engaged with and being axially displaceable in relation to the first and second members (1,2), via external threads (11,12) that are complementary to the threads (6,8) provided on the first and second members (1,2). The linear actuator furthermore comprises a sheath (4) stretching across the intermediary member (3), which sheath (4) is inrotatably, but longitudinally slidably arranged in relation to the first and second members (1,2). The linear actuator also comprises a driving rod (5) that is inrotatably, but longitudinally slidably arranged within the intermediary member (3). A medical delivery device provided with such a linear actuator is also provided.

Abstract: An apparatus for filling a cartridge with a liquid comprises, a platform on which the cartridge is supported and which can be lifted relative to a stationary filling needle (5) so that this filling needle is moved into the cartridge (6), a pump (1) feeding liquid through the filling needle (5) into the cartridge (6), a sensor head (10) from which a beam of light is sent from one side of the cartridge to the other along a path immediately over an upper edge of the cartridge (6), and a reflector (11) reflecting the light beam back to the sensor head (10), which is connected to a sensor box (12) which produces a signal stopping the pump (1) and causing the needle (5) to be drawn out of the cartridge (6) when this cartridge is full and the liquid forms a droplet over the opening of the cartridge, which droplet deflects the light beam.

Abstract: A method for preparing a compound of formula I or a salt thereof is disclosed.

Abstract: Novel insulin precursors and insulin precursor analogs comprising a connecting peptide (mini C-peptide) of preferably up to 15 amino acid residues and comprising at least one Gly are provided. The precursors can be converted into human insulin or a human insulin analog. The precursors will typically have a distance between B27 (atom CG2) and A1 (atom CA) of less than 5 Å.

Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.

Abstract: Certain compounds, structurally related to natural compounds which can be extracted i.a. from bull testes and from human follicular fluid, can be used for regulating the meiosis in oocytes and in male germ cells. Some of these compounds are useful in the treatment of infertility, whereas other compounds are useful as contraceptives. These compounds have the structural formula wherein the substituents are as defined in the specification.